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The mechanism implicated in differentiation of endogenous cardiac stem cells into cardiomyocytes to
regenerate the heart tissue upon an insult remains elusive, limiting the therapeutical goals to exogenous
cell injection and/or gene therapy. We have shown previously that cardiac speciﬁc overexpression of the
insulin-like growth factor 1 propeptide IGF-1Ea induces beneﬁcial myocardial repair after infarct.
Although the mechanism is still under investigation, the possibility that this propeptide may be involved
in promoting stem cell differentiation into the cardiac lineage has yet to be explored. To investigate
whether IGF-1Ea promote cardiogenesis, we initially modiﬁed P19 embryonal carcinoma cells to express
IGF-1Ea. Taking advantage of their cardiomyogenic nature, we analyzed whether overexpression of this
propeptide affected cardiac differentiation program. The data herein presented showed for the ﬁrst time
that constitutively overexpressed IGF-1Ea increased cardiogenic differentiation program in both undiffer-
entiated and DMSO-differentiated cells. In details, IGF-1Ea overexpression promoted localization of alpha-
actinin in ﬁnely organized sarcomeric structure compared to control cells and upregulated the cardiac
mesodermal marker NKX-2.5 and the ventricular structural protein MLC2v. Furthermore, activated IGF-
1 signaling promoted cardiac mesodermal induction in undifferentiated cells independently of cell prolif-
eration. This analysis suggests that IGF-1Eamay be a good candidate to improve both in vitro production of
cardiomyocytes from pluripotent stem cells and in vivo activation of the differentiation program of cardiac
progenitor cells.
 2011 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
The design of experimental tools for repairing postmitotic or-
gans with re-established functionality is a matter of intense re-
search in regenerative studies. In particular, upon myocardial
damage themammalian heart activates a healing process that leads
to a speciﬁc remodeling, consisting of ﬁbrotic scar formation and
cellular hypertrophy at the cost of functional muscle [1]. The
replacement and regeneration of functional cardiac muscle and
the surrounding vasculature is an important therapeutic goal. Sev-
eral strategies in mammalian tissues have been explored to poten-
tially support regeneration, which include supplementation of
growth factors that function as cyto-protectants by inhibiting
pro-death pathways, and improvement of candidate cells and their
delivery into the injured myocardium to reconstitute the losttre, National Heart and Lung
d, London UB9 6JH, United
tini).
Y-NC-ND license.vasculature and musculature. The ideal donor cell should exhibit
the structural and contractile properties of cardiomyocytes and
should be able to integrate structurally and functionally into the
host tissue. It must possess or acquire inherent properties to im-
prove colonization of the scar tissue, survive an apoptotic and
ischemic environment, and retain an initial high proliferative
capacity [2]. Therefore, potential use of pluripotent or totipotent
stem cells to replace tissue loss depends in part on efﬁcient differ-
entiation protocols to derive tissue-speciﬁc cells. It is known that
Nodal and Wnt inhibition regulates formation of cardiomyocytes
in mouse embryonic stem cells (mESCs) [3,4]. Furthermore, chem-
ical mediators of cardiogenesis have been reported in mESCs,
including cardiogenols, ascorbic acid, isoxazolyl-serines, sulfonyl
hydrazones and DMSO [5,6]. Recently, it has been shown that phar-
macological inhibition ofWnt signaling is sufﬁcient to drive human
mesoderm cells to form cardiomyocytes [7]. Nevertheless, although
culture and differentiation techniques have improved [8,9], it re-
mains challenging to obtain cardiomyocyte-enriched cultures, and
the possibility to use exogenous cell therapy is therefore limited
by this experimental gap. A promising tool would be to elicit
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myocytes to re-establish at least the lost musculature.
On this note, we recently demonstrated that the propeptide of
the insulin-like growth factor 1 family IGF-1Ea, expressed in trans-
genic mouse muscle under cardiac-speciﬁc post-mitotic control,
induces cardiac recovery by decreasing scar formation and increas-
ing cell proliferation [10]. Although the mechanism is still under
investigation, a possibility arising from our data is that IGF-1Ea
may promote endogenous stem cell proliferation and differentia-
tion into the cardiac lineage. Interestingly, previous analysis
showed that inhibition of the PI3K in cultured ESCs induced de-
creased alpha-actinin staining and embryoid body (EB) beating
areas, suggesting that the signaling mediated by PI3K leads to car-
diogenesis [11]. Recently, IGF-1 has been identiﬁed as a mediator
of Yap signaling to induce cardiomyocyte proliferation and survival
during development [12]. Nevertheless, the direct involvement of
the IGF-1 propeptides has not yet explored.
In order to investigate the possibility of using IGF-1Ea in a ther-
apeutic-like approach to elicit endogenous differentiation of car-
diac stem cells, we manipulated the growth and cardiomyocyte
differentiation potential of P19 embryonal carcinoma cell lines
expressing green ﬂuorescent protein (GFP) under the control of
the speciﬁc cardiac promoter myosin light chain 2v (MLC2v) [13].
We infected these cells with a lentivirus expressing Igf-1Ea gene
and analyzed whether transgene overexpression could favor car-
diomyocyte formation.
Our data show that overexpression of IGF-1Ea promoted in-
creased cardiomyocyte markers’ regulation and mature sarcomeric
structures’ formation in DMSO-treated cells. Furthermore, the pool
of undifferentiated cells was stimulated to express mesodermal
markers associated with cardiac lineage differentiation. Although
cardiomyocyte number was not affected, the usage of this factor
may be important to promote cardiogenesis for exogenous and/
or endogenous therapies.2. Materials and methods
An expanded Section 2 can be found in the online supplement.
2.1. Flow cytometry analysis and cell-sorting
Sorting and determination of the percentage of GFP positive
cells was performed using a FACS Aria (BD, Bekton Dickinson). Con-
ﬂuent adherent differentiated (14 days post differentiation) and
undifferentiated control and overexpressing IGF-1Ea cells were
washed with 1 PBS and trypsinized. The cell suspension was ﬁl-
tered through a 30 lm sieve (Filcon, BD) and Sytox blue (Invitro-
gen) dye was added to discriminate alive from dead cells.
Undifferentiated cells were used as negative control. For the cell
sorting, a 100 lm nozzle (20 PSI) was used.
2.2. Transduction of P19-GFP cells
Transductions were performed following the protocol provided
by the company (Invitrogen, ViraPower T-Rex Lentiviral Expression
System User Manual, 2004). In summary, transduction was per-
formed with 1 ml of pLenti4/TO/V5-DEST carrying IGF-1Ea cDNA
in culture media containing Polybrene (Sigma, 6 ll). Cells were se-
lected with zeocin (200 lg/ml), expanded and clones used for fur-
ther experiments.
2.3. Statistical analysis
Statistical analyses were performed using GraphPad Prism 4. All
measurements are reported as values ± standard error of the mean(SEM). Analysis of variance (ANOVA) or Student’s t-test was used to
analyze signiﬁcance among the samples as indicated. A signiﬁcant
difference was considered when p < 0.05 and was marked as (⁄) for
p < 0.05, (⁄⁄) for p < 0.01 and (⁄⁄⁄) for p < 0.001.3. Results
3.1. Generation of P19-GFP cells expressing IGF-1Ea
To analyze the function of IGF-1Ea propeptide in regulation of
cardiac differentiation program, we made use of the pluripotent
P19-GFP embryonal carcinoma cells [13]. These cells presented a
clear advantage in this study, since they readily differentiate into
cardiomyocytes by embryoid body techniques [13] and bona ﬁde
ventricular cardiomyocytes could be easily identiﬁed and sorted
by FACS analysis through the cardiac speciﬁc expression of GFP.
To induce the expression of the propeptide IGF-1Ea we generated
a lentiviral vector carrying IGF-1Ea under the control of the CMV
promoter (Fig. 1A). We selected by antibiotic resistance 16 stably
transduced clones, of which 6 clones expressed high levels of
IGF-1Ea (Fig. 1B). Clone 6 was selected for further experimentation,
since it formed morphologically normal embryoid bodies and dif-
ferentiate readily in ventricular cardiomyocytes [13], as shown
by overexpression of GFP under the control of the MLC2v promoter
(Supplementary Fig. 1A and B). P19-GFP cells transduced with an
empty lentiviral vector served as control.
To verify whether differentiation into the cardiomyocytes line-
age preserved IGF-1Ea expression, cells were treated with DMSO
1% and plated for 12 days on Petri dishes to allow formation of
beating areas. Real time PCR (RT-PCR) data showed that expression
of IGF-1Ea is increased signiﬁcantly upon DMSO-induced cardiac
differentiation (Fig. 1C). In parallel, IGF-1 mean relative expression
of control cells after cardiomyocyte-induced differentiation
showed upregulation of the IGF-1 transcript (Fig. 1C), indicating
that differentiation into the cardiac lineage correlates with endog-
enous IGF-1 overexpression.
Taken together, these data indicate that constitutive expression
of the gene of interest is ensured in undifferentiated and differen-
tiated P19 teratocarcinoma cells using this lentiviral system.3.2. IGF-1Ea activates PDK1 signaling and cell survival mechanisms
but does not change cell cycle proﬁle
To analyze whether IGF-1 signaling pathway is induced in cells
overexpressing IGF-1Ea compared to control cells, cell extracts
were analyzed for activation of the downstream mediators of
IGF-1 signaling, PDK1 and AKT1. The results in Fig. 1D showed that
overexpression of IGF-1Ea induced signiﬁcant increase of PDK1
phosphorylation at residue Ser241 without affecting AKT1 phos-
phorylation levels compared to empty vector-transduced control
cells (Fig. 1D). The data reported are in agreement with our previ-
ous analysis performed on IGF-1Ea overexpressing hearts [10],
indicating that the downstream signaling activated by this speciﬁc
propeptide is not mediated by AKT1 but employes a novel pathway
in both mammalian heart and pluripotent teratocarcinoma cells.
Signaling pathways mediated by IGF-1 increase skeletal muscle
and cardiac survival [14]. To verify whether overexpression of IGF-
1Ea induced protective signaling, we mimicked infarct conditions
in vitro exposing control and IGF-1Ea overexpressing cells to hy-
poxia (Fig. 2A). The effects of hypoxia on cell viability were quan-
tiﬁed by measuring the activity of lactate dehydrogenase (LDH)
released into the medium. LDH activity was signiﬁcantly increased
in both control and IGF-1Ea cells compared to normoxia-treated
cells. Importantly, IGF-1Ea overexpression decreased LDH activity
Fig. 1. Characterization of P19-GFP embryonal carcinoma cells expressing IGF-1Ea. (A) The pLenti4/TO/V5-DEST contains the recombination sites attR1 and attR2
downstream the CMV-TO promoter that allowed recombination between this lentiviral vector and the one carrying IGF1Ea. (B) Transduced clones constitutively expressed
IGF-1Ea transcripts. IGF-1 expression was analyzed by a rodent IGF-1 probe. 18S rRNA was used as internal reference gene. Values are Mean +/ SEM. (C) IGF-1Ea Clone 6 cells
and control Clone 6 cells were differentiated in 1% DMSO and RNA extracts analyzed for quantitative Real Time PCR (qRT-PCR). 18S rRNA was used as internal reference gene.
Results are expressed as mean ± SEM. (D) Undifferentiated P19-GFP cells expressing IGF-1Ea (lane 1) and control cells (lane 2) were analyzed for PDK1 and AKT1 activity.
Normalization was performed with total AKT1 and PDK1. The ﬁgure shows the analysis of three independent experiments and their fold induction values in the right panel.
Asterisk (⁄) indicates signiﬁcant values (p < 0.05); ns, no signiﬁcant.
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protective role of IGF-1Ea to low oxygen conditions.
IGF-1 regulates proliferative response in different cell types
in vitro [15,16] and during embryonic development [17]. Interest-
ingly, G1, S and G2 cell cycle phases measured by ﬂow cytometric
analysis are comparable between control and IGF-1Ea cells, indi-
cating that the signaling cascade mediated by this speciﬁc propep-
tide did not alter cell cycle in this clone (Fig. 2B). We report here
that an altered proliferative proﬁle was however observed in three
of the 16 clones (e.g. clone 5, Supplementary Fig. 2), suggesting
that the site of insertion rather than the expression of the growth
factor causes cell cycle differences.
Taken together, these data showed that IGF-1Ea activates pro-
survival signaling as assessed in the in vivo cardiac model, without
altering cell cycle proﬁle.
3.3. Cardiac mesoderm formation is increased by IGF-1Ea
overexpression in undifferentiated P19-GFP cells
It has been reported that PI3K signaling induces cardiac com-
mitment in ES cells, suggesting that activators of this kinase such
as IGF-1, TGFbeta, FGF, and insulin may promote cardiogenesisin vitro [18]. To test whether overexpression of the IGF-1Ea pro-
peptide in undifferentiated P19-GFP cells was associated with a
gene expression proﬁle that correlates with ectodermal, endoder-
mal or mesodermal lineage speciﬁcation, we analyzed by RT-PCR
the level of vimentin, GATA4, Otx2 and Nodal transcripts. Inter-
estingly, we observed that vimentin, reported to favor cell migra-
tion into the primitive streak, is upregulated in the selected clone
(Fig. 2C). The ectodermal marker Otx2 [19] is signiﬁcantly down-
regulated, whereas the early endodermal marker GATA4 [20]
(Fig. 2D and E) remained comparable to control cells. The meso-
dermal marker nodal was upregulated in IGF-1Ea expressing cells
and this correlated with induction of the early cardiac marker
NKX-2.5 (Fig. 2F and G). To distinguish whether this gene expres-
sion proﬁle is a result of IGF-1Ea activity and it is not caused by
differential site integration of the gene, we analyzed the above
markers in the remaining clones (Supplementary Fig. 3). The data
showed that Otx2 is signiﬁcantly decreased in all clones (Supple-
mentary Fig. 3A), whereas Vimentin (Supplementary Fig. 3B), no-
dal and NKX-2.5 (Supplementary Fig. 3C and D) signiﬁcantly
increased in the majority of the clones. Taken together, the data
indicate that IGF-1Ea is a speciﬁc regulator of mesodermal cardiac
induction in uncommitted cells.
Fig. 2. IGF-1Ea regulation of survival, proliferation and lineage commitment in undifferentiated P19-GFP cells. (A) P19-GFP/IGF-1Ea and control P19-GFP cells were exposed
to 3% hypoxia for 24 h. Percentage of LDH activity was measured as described in Supplementary Materials and Methods by comparison of IGF-1Ea and control cells in
normoxic (white bars) and hypoxic (black bars) conditions. Signiﬁcance was measured by one-way ANOVA and ⁄⁄ indicates p < 0.01, whereas ⁄⁄⁄ indicates p < 0.001. (B) Cell
cycle analysis of undifferentiated P19Cl6 cells, transduced with empty (blue) or IGF-1Ea (red) viral vectors. Percentage of cells in S phase were similar in both empty and IGF-
1Ea expressing cells. Results were obtained by PI staining using Flow Jo analyses. X-axis represents percentage of cells and y-axis ﬂuorescent intensity. (C–G) qRT-PCR analysis
for the mesodermal markers vimentin (C) and nodal (F), the ectodermal marker Otx2 (D), the endodermal GATA4 (E) and the cardiac marker NKX-2.5 (F) in undifferentiated
IGF-1Ea and control cells. 18S rRNA was used as internal reference gene. Results are expressed as mean ± SEM. Asterisk (⁄) indicates signiﬁcant values (p < 0.05); ⁄⁄ indicates
p < 0.01, whereas ⁄⁄⁄ indicates p < 0.001. (For interpretation of the references in color in this ﬁgure legend, the reader is referred to the web version of this article.)
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differentiation in DMSO-treated cells without affecting their number
As shown previously, inhibition of the IGF-1-mediated signaling
pathway abolishes cardiac commitment in ES cellswithout affecting
endothelial cell formation [11,21]. As a result, induced IGF-1 overex-
pression could lead to increased amount of cardiacmuscle cells or to
amore differentiated state. Therefore,we initially analyzedwhether
the amount of ventricular cardiomyocytes, assessed by FACS analy-
sis of GFP positive cells, is increased in IGF-1Ea transduced cells. As
shown in Fig. 3A, the percentage of FACS-sorted GFP cells is compa-
rable between IGF-1Ea transduced cells and control cells, indicating
that IGF-1Ea overexpression did not alter the percentage of ventric-
ular cardiomyocytes formed after DMSO-induced differentiation
(Fig. 3A). To test whether IGF-1 overexpression correlates with in-
creased cardiomyogenic differentiation, real time PCR of cardiac
markers (Fig. 3B–D) and immunoﬂuorescent stainingwith the struc-
tural sarcomeric protein alpha-actinin (Fig. 4) was performed in dif-
ferentiated clone 6 and control cells. Interestingly, we observed that
IGF-1Ea induced signiﬁcant upregulation of NKX-232.5 and MLC2vin DMSO-treated cells compared to undifferentiated IGF-1Ea
transduced cells, as well as differentiated control cells (Fig. 3B and
C).Whenwemeasured the relative fold induction of the early endo-
dermal and mesodermal marker GATA4 we noticed a signiﬁcant in-
creased in control cells upon DMSO-induced cardiac differentiation
(Fig. 3D). Interestingly, IGF-1Ea overexpression decreased GATA4
upregulation (Fig. 3D) compared to differentiated control cells, sug-
gesting that this speciﬁc IGF-1 propeptide may induce cardiomyo-
genic differentiation by regulating the expression of the early
mesodermal and endodermal markers. To investigate whether the
increased cardiac muscle markers correlated with mature cytoskel-
etal organization, IGF-1Ea clone 6 and control transduced cells were
stained with alpha-actinin and the ventricular speciﬁc population
was identiﬁed by GFP expression (Fig. 4). IGF-1Ea transduced cells
showed localization of alpha-actinin in ﬁnely organized sarcomeric
structure compared to control cells and to rat neonatal cardiomyo-
cytes (Fig. 4). Taken together, the in vitro analysis showed that
overexpression of IGF-1Ea correlates with increased cardiac differ-
entiation upon DMSO-treatment. This response was not associated
with increased GFP positive cell number.
Fig. 3. Differentiation program mediated by IGF-1Ea. (A) Percentage of GFP positive cells expressing IGF-1Ea and control cells quantiﬁed by FACS analysis. The analysis was
performed in ﬁve independent experiments. Values are mean ± SEM. Signiﬁcance was analyzed by Student’s t-test and p = 0.52. (B–D) qRT-PCR analysis for cardiac speciﬁc
marker expression in IGF-1Ea and control cells in DMSO-differentiation conditions. (B) Nkx2.5, (C) MLC2v and (D) GATA4 expression were normalized by measuring levels of
18S rRNA.
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The limited potential of the mammalian myocardium for self-
repair and renewal entails the necessity to ﬁnd efﬁcient molecular
and cellular targeting repairing the scarred heart and improving
cardiac function after myocardial ischemic disease.
One possibility is to mobilize endogenous cells able of regener-
ating the infarcted heart by differentiation into cardiomyocytes
and endothelial cells. Alternatively, exogenous sources of cells
should be used to replace damaged cardiac tissue.
Either ways are limited by the low number of cells capable of
differentiating into contractile cardiomyocytes in order to repopu-
late the extensive loss of tissue occurring after myocardial infarct.
Our previous data showed that the insulin-like growth factor 1
propeptide IGF-1Ea induced cardiac repair after infarct by lowering
scar formation and maintaining tissue integrity. To investigate the
possibility that this propeptide can elicit cardiac lineage differenti-
ation, in this manuscript we analyzed the effect of IGF-1Ea on plu-
ripotent stem cells. As proof of principle, we used P19 embryonal
carcinoma cells expressing GFP under the control of the cardiac
speciﬁc promoter MLC2v. To ensure long-term constitutive expres-
sion of IGF-1Ea, we cloned Igf-1Ea cDNA into a lentiviral backbone.
We selected 16 clones and clone 6 showed normal embryoid body
formation and cardiomyocyte differentiation. Our initial in vitroanalyses showed that IGF-1Ea was highly expressed in transduced
P19-GFP cells and that overexpression was retained after DMSO-
induced cardiac cell differentiation. Interestingly, expression of
IGF-1 was upregulated also in differentiated control cells, indicat-
ing that DMSO-induced cardiac differentiation activates endoge-
nous IGF-1 transcription.
Furthermore, IGF-1Ea induced increased cell survival upon hyp-
oxic conditions and did not alter cell cycle. This was advantageous
in our system, since proliferative signaling could change the
expression of transcription factors, undermining the role of IGF-
1Ea in regulating the differentiation program. In this manuscript,
we aimed to understand whether the propeptide has a role in car-
diogenesis for therapeutical use. We have observed that IGF-1Ea
overexpression in undifferentiated cells correlated with increased
vimentin and nodal expression. Vimentin is an intermediate ﬁla-
ment found in mesenchymal cells [22]. Although vimentin knock-
out mice (vim/) have mild phenotype [23], it has been observed
that migratory-deﬁcient vim/ ﬁbroblasts failed to heal wounded
epithelial tissue and that vim/ lymphocytes have impaired trans-
migration and extravasation capacities [24,25]. The above data ar-
gue for a role of vimentin in cell migration. On this note, in bovine
embryos the recruitment of cells from the epiblast to form the
primitive streak as well as the endoderm and mesoderm is associ-
ated with expression of the intermediate ﬁlament vimentin [26],
Fig. 4. IGF-1Ea mediated cardiomyocytes sarcomeric structure maturation. IGF-1Ea transduced cells (P19-GFP/IGF-1Ea), control cells transduced with lentivirus not
expressing IGF-1Ea (P19-GFP) were cultured after embryoid bodies’ formation on 0.1% gelatin. Cardiomyocytes (GFP labeled panels) were stained with alpha actinin
monoclonal antibody (Sigma). Nuclei were visualized by DAPI staining. Neonatal rat cardiomyocytes were used as positive control (lower panels). The measurement bar is
20 lm. The pictures are representative of two independent experiments.
298 B. Poudel et al. / Biochemical and Biophysical Research Communications 416 (2011) 293–299suggesting that vimentin can mark cells that specify the endoder-
mal and the mesodermal ﬁeld. Indeed, in our study we have found
that IGF-1Ea-mediated vimentin regulation was associated with
the presence of mesodermal but not ectodermal and endodermal
lineage differentiation, as assessed by nodal overexpression. To
our surprise upregulation of the early cardiac markers NKX-2.5
[27] was found in the undifferentiated cells, suggesting that IGF-
1Ea regulates mesodermal lineage differentiation towards the
myocardial fate in uncommitted cells.
Interestingly, IGF-1Ea potentiated the cardiogenic effects of
DMSO treatment by increasing the expression of cardiac speciﬁc
markers NKX-2.5 and MLC2v. In addition, we noted that GATA4
was downregulated by IGF-1Ea compared to control differentiated
cells, suggesting a ﬁne regulation of the endodermal/mesodermal
cell lineage component by this speciﬁc propeptide. It has been re-
ported that GATA4 is not necessary for cardiomyocyte differentia-
tion [28], but it is capable of specifying endoderm fates to facilitate
the generation of cardiomyocyte progenitors from associated
mesoderm [20]. The extent of IGF-1Ea control of cardiac differenti-
ation and endodermal/mesodermal speciﬁcation is therefore a
novelty and it will need to be further analyzed. Although IGF-1 is
recognized as a potent mitogen in neoplasia [29] and during devel-
opment [17], P19-GFP cells did not change their proliferative state
during undifferentiated conditions. This may be caused by molec-
ular and physiological differences between the in vivo and the
in vitro system. Nevertheless, under DMSO-differentiation condi-
tions the amount of GFP + cardiomyocytes remained invariant be-
tween IGF-1Ea overexpressing and control cells. On the contrary,
IGF-1Ea overexpression correlated with mature sarcomeric
structure, indicating that this speciﬁc isoform favors cardiac differ-
entiation in both undifferentiated cells and cells stimulated to dif-
ferentiate by DMSO treatment.
In addition to the above considerations, our analysis could be
important to redirect gene therapy studies. Indeed, before gene
therapy can become a permanent cure for any condition, the ther-
apeutic DNA introduced into target cells must remain functional
and the cells containing the therapeutic DNA must be long-lived
and stable. Furthermore, while viruses are the carrier of choice inmost gene therapy studies, they present a variety of potential prob-
lems to the patient such as toxicity, immune and inﬂammatory re-
sponses, as well as the ability to cause disease. These features
preclude the usage of gene therapy in large scale clinical trial.
Our study suggests that cell-mediated gene delivery could be used
to reduce the risk of ectopic expression.
Taken together, our data propose to test cell-mediated IGF-1Ea
delivery in therapeutical studies to induce cardiac stem cell differ-
entiation into cardiomyocytes in vivo and suggest to further analyze
the in vitro ability of the propeptide to elicit cardiac differentiation
of pluripotent cells for transplantation experiments.
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